BasilKasimisMD

Oncology • North Brunswick, NJ

Professor, Medicine, UMDNJ-New Jersey Medical School

Join to view full profile

Dr. Kasimis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kasimis' full profile

Already have an account?

Office
14 Lake Drive
North Brunswick
North Brunswick, NJ 08902
Phone+1 732-821-3124

Fax+1 732-821-3142
Is this information wrong?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1980
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1977 - 1979
MedStar Health/Harbor HospitalResidency, Internal Medicine, 1974 - 1977
University of AthensClass of 1970

Certifications & Licensure

NJ State Medical License Active through 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer Start of enrollment: 2002 Aug 01
Unknown status
Phase 2
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer Start of enrollment: 2002 Jul 01
Unknown status
Phase 2
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

7 citations
Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced Cancer.
Victor T. Chang, Charles Scott, Melanie L. Gonzalez, Jan Einhorn, H. Yan, Basil Kasimis> ;Journal of Pain and Symptom Management. 2015 Sep 1
5 citations
Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma.
Payam Benson, Michael Yudd, Derrick Sims, Victor T. Chang, Shanthi Srinivas, Basil Kasimis> ;Clinical Nephrology. 2012 Nov 1
Clinical characteristics of multiple myeloma (MM) in Vietnam-era (V) and non-Vietnam-era veterans (Non V).
Srinivas S, Paulin R, Abanonu C, Kim K, Soriano L, Tufail M, Kasimis B, Chang VT, Duque L, Crump B, McPherson M> ;J. Clin. Oncol.. 2011-05-20
Multiple myeloma patients at a VA Medical Center: Comorbidity and survival.
Paulin R, Srinivas S, Abanonu C, Kim K, Soriano L, Chang VT, Kasimis B, Gonzalez ML> ;J. Clin. Oncol.. 2011-05-20
Comorbidity as a predictor of survival in veterans with stage I and II non-small cell lung cancer (NSCLC).
Boholli I, Hoover D, Yang WM, Abanonu C, Gonzalez M, Kasimis B, Chang VT> ;J. Clin. Oncol.. 2011-05-20
The Gleason score (GS) as a predictor of survival in stage D2 and D3 prostate cancer (PC).
Kasimis B, Chang VT, Gonzalez ML, Srinivas S, Zhong F, Duque L, McPherson M, Einhorn J, Crump B, Blumenfrucht M> ;J. Clin. Oncol.. 2011-05-20
Multidimensional model of hope and survival in patients with advanced cancer.
Scott CB, Chang VT, Gonzalez ML, Einhorn J, Yan H, Zhou B, Crump B, Kasimis B> ;J. Clin. Oncol.. 2011-05-20
Comparison of outcomes of patients with hepatocellular carcinoma (HCC) over 2 consecutive decades for a VA population.
Zhong F, Kim K, Chang V, Gonzalez ML, Quainoo C, McPherson M, Crump B, Einhorn J, Kalwar T, Kasimis B> ;J. Clin. Oncol.. 2011-05-20
Chronic lymphocytic leukemia (CLL) patients at a VA medical center: Comorbidity and survival.
Soriano L, Srinivas S, Tufail M, Kim K, Paulin R, Chang VT, Kasimis B, Gonzalez ML> ;J. Clin. Oncol.. 2011-05-20
2 citations
Asymptomatic mantle cell lymphoma in the trachea.
Sivaraman Kuppusamy Gounder, Manzurul Sikder, S. Srinivas, Victor T. Chang, Basil S. Kasimis> ;Leukemia & Lymphoma. 2009 Jul 1
Prediction of survival by immunohistochemical stains (IHC) in stage D2 prostate cancer patients (pts): The importance of pTEN overexpression.
Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, Srinivas S, Cogswell J, Morales E, Ahmed S> ;J. Clin. Oncol.. 2009-05-20
Comorbidity and survival of hepatocellular carcinoma patients at a VA medical canter.
Zhong F, Oliphant T, Chang VT, Crump B, Gonzalez ML, McPherson M, Morales E, Duque L, Einhorn J, Kasimis B> ;J. Clin. Oncol.. 2009-05-20
Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients.
Chang VT, Hoover DR, Cogswell J, Cholankeril M, Badin S, Yang W, Yan H, Gonzalez ML, Einhorn J, Kasimis BS> ;J. Clin. Oncol.. 2009-05-20
Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment.
Srinivas S, Cholankeril M, Chang VT, Morales-Muyuela E, Duque L, Toomey K, Kasimis B> ;J. Clin. Oncol.. 2009-05-20
Prostate cancer immunohistochemical (IHC) stains and survival in stage D3 patients (pts).
Gounder SK, Chang VT, Hoover D, Gonzalez ML, Ahmed S, Finch-Cruz C, Duque L, Zhong F, Toomey K, Kasimis BS> ;J. Clin. Oncol.. 2008-05-20
End-of-life quality-of-care indicators for medical oncology patients at a VA medical center.
Chang VT, Bhatty MU, Hoover D, Sikder MA, Gounder S, Gonzalez ML, McPherson M, Zhong F, Nazha NT, Kasimis BS> ;J. Clin. Oncol.. 2008-05-20
Non-Hodgkin's lymphoma patients at a VA medical center: Co-morbidity and its impact on survival.
Cholankeril M, Srinivas S, Chang VT, Demissie K, Gonzalez ML, Zhong F, Crump B, McPherson M, Einhorn J, Kasimis BS> ;J. Clin. Oncol.. 2008-05-20
Comorbidity and survival of prostate cancer D3 patients.
Cogswell J, Badin S, Oliphant TL, Hoover D, Chang VT, Gonzalez ML, Gounder SK, Duque L, Srinivas S, Kasimis BS> ;J. Clin. Oncol.. 2008-05-20
Processes as predictors of outcomes of EOL care at a VA medical center.
Gonzalez ML, Chang VT, Hoover D, Bhatty MU, Gounder SK, Sikder MA, Wu HV, Cogswell J, Crump B, Kasimis BS> ;J. Clin. Oncol.. 2008-05-20
Correlation between prostate cancer immunohistochemical stains (IHC) and survival in stage D2 patients(pts).
Kasimis BS, Chang V, Gounder S, Hoover D, Finch-Cruz C, Cogswell J, Gonzalez ML, Morales E, Srinivas S, Blumenfrucht M> ;J. Clin. Oncol.. 2008-05-20
32 citations
Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer
Saby George, Basil Kasimis, J. Cogswell, Paul Schwarzenberger, Geoffrey I. Shapiro, Panos Fidias, Ronald M. Bukowski> ;Clinical Lung Cancer. 2008 May 1
Combination therapy with docetaxel (D) and celecoxib (C) in patients (pts) with hormone resistant prostate cancer (HRPC).
Kasimis B, Chang V, Cogswell J, Sambamoorthi N, Gonzalez M, Srinivas S, Zhong F, Morales E, Duque L, Blumenfrucht M> ;J. Clin. Oncol.. 2006-06-20
A phase II trial of epirubicin (E), estramustine phosphate (EP), and celecoxib (C) as second line treatment of patients (pts) with hormone resistant prostate cancer (H...
Zhong F, Kasimis B, Chang V, Sambamoorthi N, Srinivas S, Cogswell J, Morales E, Gonzalez M, Duque L, Blumenfrucht M> ;J. Clin. Oncol.. 2006-06-20
Quality of life (QOL) in patients (Pts) with hormone resistant prostate cancer (HRPC) treated with docetaxel (D) and celecoxib (C).
Chang VT, Sambamoorthi N, Yan H, Gonzalez M, Cogswell J, Srinivas S, Zhong F, Crump B, Blumenfrucht M, Kasimis BS> ;J. Clin. Oncol.. 2006-06-20
28 citations
The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) Appetite Scale in veteran cancer patients.
Victor T. Chang, Qi Xia, Basil Kasimis> ;The Journal of Supportive Oncology. 2005 Sep 1
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Veterans Affairs New Jersey Health Care SystemEast Orange, New Jersey